Clinical Trials · NCT05485818
Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Beijing Northland Biotech. Co., Ltd.
- Enrollment
- 62
- Start date
- Nov 2020
- Locations
- 1 site, China
- Primary endpoint
- Change of myocardial infarction area on Day 5 and day 90 after PCI